Classification and Management of Heart Failure

Introduction to Heart Failure Classification

The American College of Cardiology and American Heart Association (ACC/AHA) classify heart failure into four stages (A-D) based on disease progression, which is essential for guiding treatment and stratifying risk 1.
The New York Heart Association (NYHA) functional classification evaluates symptom severity, ranging from Class I (no limitation) to Class IV (inability to perform any physical activity without symptoms) 1, 5.

The ACC/AHA staging system categorizes heart failure based on disease progression: Stage A (at risk), Stage B (pre-heart failure), Stage C (symptomatic heart failure), and Stage D (advanced heart failure) 1, 2, 3, 4.
The NYHA classification system assesses symptom severity: Class I (no limitation), Class II (mild limitation), Class III (marked limitation), and Class IV (severe limitation) 1, 5.

The Killip classification provides a clinical estimate of the severity of circulatory impairment in acute myocardial infarction: Class I (no heart failure), Class II (heart failure with rales and S3 gallop), Class III (severe heart failure with pulmonary edema), and Class IV (cardiogenic shock) 5, 6.
The Forrester classification describes the clinical and hemodynamic state based on perfusion and pulmonary capillary wedge pressure (PCWP) in acute myocardial infarction 5.

The European Society of Cardiology identifies six distinct presentations: acute decompensated heart failure, hypertensive heart failure, pulmonary edema, cardiogenic shock, high-output failure, and right-sided heart failure 7.

Heart failure is classified based on left ventricular ejection fraction (LVEF): reduced LVEF (HFrEF, <40%), mildly reduced LVEF (HFmrEF, 41-49%), and preserved LVEF (HFpEF, ≥50%) 1, 8.

Identifying precipitating factors is crucial, as it guides appropriate therapy: non-adherence to medication, uncontrolled hypertension, acute myocardial ischemia, arrhythmias, and anemia 9, 6.

Mortality varies significantly based on NYHA class and clinical context: Class II (7-15% mortality), Class III (12-26% mortality) 8.

Electrocardiogram (ECG) and serum biomarkers, including cardiac troponin, should be used to rapidly identify acute coronary syndrome precipitating acute decompensated heart failure 6.
ECG should be performed in all patients with suspected heart failure; if completely normal, systolic heart failure is unlikely (<10%) 5.
Natriuretic peptides (BNP and NT-proBNP) confirm the diagnosis: BNP <100 pg/mL or NT-proBNP <400 pg/mL (heart failure unlikely), BNP 100-400 pg/mL or NT-proBNP 400-2000 pg/mL (diagnosis uncertain), and BNP >400 pg/mL or NT-proBNP >2000 pg/mL (heart failure likely) 5, 10.